Scientists Concerned About Future of International Collaboration

Policies that limit researchers’ travel could restrict scientific progress and partnerships.

Written byAbby Olena, PhD
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ISTOCK, JAMIELAWTONFor more than 10 years, Mustafa al’Absi, a behavioral scientist at the University of Minnesota, has been collaborating with researchers in Yemen to study the neurological and behavioral effects of chewing a psychostimulant plant called khat. But the collaboration faced challenges in recent years due to the tenuous security situation in Yemen. And following Trump’s executive order limiting immigration from Yemen and five other countries with predominately Muslim populations, al’Absi decided to put the project on hold completely to avoid burdening his colleagues with concern over travel.

“The conversation has been a bit toxic when it comes to welcoming or not welcoming scientists from abroad . . . not just in regions that have been affected by these policies,” al’Absi explains. “It’s a difficult situation, even without thinking about specific policies or specific enactment of policies. I always am concerned about perception because that’s what drives people.”

And al’Absi isn’t alone. In an age of shifting political climates—namely, Brexit and policies such as US President Donald Trump’s executive order on immigration—many researchers are rethinking how they approach international collaborations, as uncertainty abounds about the effects of limiting scientists’ global mobility.

Issues of travel, funding, and collaboration “are closely linked in people’s minds,” says Andrew Rosenberg, a marine scientist and the director of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies